Melioidosis, Suspected or Confirmed Bloodstream Infections, Systemic Inflammatory Response Syndrome
Conditions
Keywords
Blood infection, melioidosis, rapid diagnostic test
Brief summary
Clinical samples \[blood and voided urine (only for phase A)\] from patient recruited at Sihanouk Hospital Centre of HOPE (SHCH) and HOPE Community Medical Center (CMC) will be processed (decontamination) and shipped to SRI International with the purpose of design and validation (proof of concept) and (case/control series) of in-vitro diagnostics for melioidosis.
Detailed description
Study will be proposed to all patients at Sihanouk Hospital Centre of HOPE (SHCH) and HOPE Community Medical Center (CMC) presenting with systemic inflammatory response syndrome (SIRS). Blood samples will be collected upon admission for patients with blood culture request as part of routine patient care and agreement on informed consent. A second sample will be collected in patients with blood culture proven melioidosis or suspicion of melioidosis (only for phase B), at day 5 after initiation of appropriate antibiotic treatment. Depending on the final diagnosis, a subset of patients will be assigned to 3 groups: 1. Patients for whom blood cultures grew Burkholderia pseudomallei 2. Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis 3. Patients for whom blood cultures grew with another pathogen In phase A only, at least 20 ml of voided urine will be collected when a patient is hospitalized and identified as belonging to study group 1, 2 or 3. A second collection of voided urine will be collected for group 1 and 2 patients during routine further hospital stay or a routine follow-up visit. The clinical samples from these patients will be processed and shipped to SRI International with the purpose of design (=phase A) and validation (=phase B) of in-vitro diagnostics for melioidosis. A coded database will be completed with basic demographic, clinical and microbiological data and final diagnosis. This coded information will be provided to SRI International.
Interventions
OTHERVenous blood sampling (2 timepoints) (Phase A and B)
8.5ml at Day 1 + 8.5ml at Day 5
OTHERVenous blood sampling (1 timepoint) (Phase A and B)
8.5ml at Day 1
OTHERVoided urine sampling (first sample) (Phase A)
At least 20ml upon confirmation of being part of one of the 3 study groups
OTHERVoided urine sampling (second sample) (Phase A)
At least 20ml during routine hospital stay or routine follow-up visit
Sponsors
Sihanouk Hospital Center of HOPE
SRI International
Institute of Tropical Medicine, Belgium
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult (\>18 years old) * Blood culture request by treating physician as part of standard care * Willing to give informed consent
Exclusion criteria
* Refusal to give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical reference panel (blood) | 15 months | Establishment of a quality-assured and well-documented clinical reference panel (cases/control) of human blood samples allowing for the design, development and proof-of-concept validation of an in-vitro diagnostic assay for the diagnosis of melioidosis. |
| Clinical reference panel (urine) | 15 months | Establishment of a quality-assured and well-documented clinical reference panel (cases/control) of human voided urine samples allowing for the design, development and proof-of-concept validation of an in-vitro diagnostic assay for the diagnosis of melioidosis. |
Countries
Cambodia
Outcome results
None listed